Assertion: lymphoma's treatment | /r/CapableOf | achieve overall response
Facets:
value: with percentage responses
type: OTHER
value: with progression-free survival rate
type: OTHER
value: respectively
type: MANNER
Source sentences:
text: A phase II clinical trial has found that the treatment of SMZL with a combination of rituximab plus bemdamustine achieves overall response and complete response rates of 91% and 73%, respectively, with percentage responses enduring for >3 years, progression-free survival rate, and overall survival rate of 93%, 90%, and 96%, respectively.